Table 1 Main characteristics of studies
Author | No. of Patients | Sampling time | CTCs or DTCs | Detection methods | Markers | Definition of positive | Outcome measures | Results |
|---|---|---|---|---|---|---|---|---|
[17] | 80 | Pre-therapy | CTC | RT-PCR | MAGE-As | ≥1 tumor-associated transcript over expressed | OS & PFS/DFS | Positive for PFS/DFS and OS |
[18] | 129 | Pre-therapy | CTC | CAM-initiated CTC enrichment or identification | EpCAM, CD45 clone 5B1 and CD66b | iCTCs ≥ 5 | OS & PFS/DFS | Positive for PFS/DFS and OS |
[19] | 143 | Pre-therapy | CTC | RT-PCR | EpCAM, MUC1,or MUC16 | ≥1 tumor-associated transcript over expressed | OS & PFS/DFS | Positive for PFS/DFS and OS |
[35] | 216 | Pre-therapy and post-therapy | CTC | RT-PCR | PPIC, GPX8, CDH3, TUSC3, COL3A1, LAMB1, MAM, ESRP2, AGR2, BAIAP2L1, TFF1, EpCAM | ≥1 tumor-associated transcript over expressed | OS & PFS/DFS | Negative pre-therapy but positive for post-therapy |
[34] | 216 | Pre-therapy | CTC | CellSearch (IHC) | EpCAM | ≥2 cell stained | OS & PFS/DFS | Positive for PFS/DFS; negative for OS |
[26] | 122 | Pre-therapy and/or post-therapy | CTC | RT-PCR | EpCAM, MUC-1, HER2 A45-B/B3 (BM) | ≥1 tumor-associated transcript over expresse ≥1 CK cell positive (BM) | OS & PFS/DFS | CTC: positive for OS but negative for PFS/DFS; DTC: negative for PFS/DFS and OS |
[20] | 90 | Pre-therapy | DTC | IHC | A45-B/B3 | ≥1 cell positive | OS & PFS/DFS | Positive for PFS/DFS and OS |
[37] | 112 | Pre-therapy | DTC | IHC | A45-B/B3 | ≥1 CK cell positive | OS & PFS/DFS | Positive for PFS/DFS but negative for OS |
[21] | 62 | Pre-therapy and post-therapy | DTC | IHC (Epimet® kit) | A45-B/B3 | ≥1 CK cell positive | OS & PFS/DFS | Positive for PFS/DFS and OS |
[22] | 69 | Pre-therapy | DTC | IHC | A45-B/B3 | ≥1 CK cell positive | PFS/DFS | Positive for PFS/DFS |
[24] | 90 | Pre-therapy | CTC/DTC | IHC | MOC-31 | Presence of ≥2 rosettes (≥5 beads bound to a cell) | OS & PFS/DFS | Negative for PFS/DFS and OS |
[5] | 59 | Pre-therapy | CTC | IHC | CK8 and 18 TFS-2, CK7, CK20 EGFR | ≥1 cell positive | OS & PFS/DFS | Negative for PFS/DFS and OS |
[25] | 66 | Pre-therapy | CTC | Cell invasion assay | EpCAM | ≥1 cell positive | OS & PFS/DFS | Positive for PFS/DFS; Negative for OS |
[23] | 43 | Pre-therapy and intra-therapy | CTC | CellSearch (IHC) | EpCAM | ≥1 cell positive | OS & PFS/DFS | Negative for PFS/DFS and OS |
[6] | 57 | Pre-therapy and intra-therapy | DTC | IHC (Epimet® kit) | A45-B/B3 EpCAM | ≥1 cell positive | PFS/DFS | Positive for PFS/DFS |
[38] | 69 | Pre-therapy | DTC | IHC | A45-B/B3 | ≥1 CK cell positive | PFS/DFS | Negative for PFS/DFS |